BACKGROUND: Human papillomavirus vaccination may result in lowered intention to be screened for cervical cancer, potentially leading to gaps in screening coverage and avoidable cervical cancer diagnoses. OBJECTIVE: The purpose of this study was to examine the association between human papillomavirus vaccination and subsequent cervical cancer screening initiation and adherence to recommended screening intervals to detect gaps in screening coverage and inform future prevention efforts. STUDY DESIGN: A retrospective cohort study was conducted in 2 distinct cohorts of female members of Kaiser Permanente Southern California, which is a large integrated healthcare delivery system. Papanicolaou screening initiation was evaluated in women who reached 21 years from 2010e2013. Adherence to recommended screening intervals was evaluated in women who were 25e30 years old in 2010. All women were observed to the end of 2013 for the evaluation of their screening behaviors. History of human papillomavirus vaccination and Papanicolaou screening were obtained from electronic medical records. Adherence to recommended screening intervals was measured as !85% vs <85% of the observed "screening up-to-date" person-time. Multivariable Cox and logistic regression models were used to examine associations between vaccination history and screening initiation and interval adherence. Demographic characteristics, gynecologic health history, healthcare use,
and characteristics of women's primary care providers were included as potential confounders in the analyses. RESULTS: There were 27,352 and 41,328 women included in the screening initiation and screening interval adherence analyses, respectively. In comparison with unvaccinated women, adjusted hazard ratios (95% confidence intervals [CIs] ) for screening initiation among women who had been vaccinated against human papillomavirus were 1.19 (95% CI, 1.11e1.28), 1.44 (95% CI, 1.34e1.53), and 1.57 (95% CI, 1.50e1.65) for 1, 2, and !3 doses, respectively. Adjusted odds ratios for screening interval adherence were 0.93 (95% CI, 0.83e1.04), 1.73 (95% CI, 1.52e1.97), and 2.29 (95% CI, 2.05e2.56), for 1, 2, and !3 doses, respectively. CONCLUSION: Women who had been vaccinated against human papillomavirus in this community-based, integrated healthcare setting were more likely to be screened for cervical cancer than were unvaccinated women. Our findings underscore the need for targeted interventions among unvaccinated women who may be disproportionally affected by cervical cancer, despite the presence of population-based screening programs.
I mmunization with the human papillomavirus (HPV) vaccine does not eliminate the need for routine cervical cancer screening because currently available HPV vaccines do not offer complete protection against all oncogenic HPV types. Also, vaccination does not always occur at the recommended ages (ie, 11e12 years old), 1 which increases the chance of exposure to oncogenic HPV before vaccination. Furthermore, many of those who receive the vaccine are not vaccinated according to the recommended dosing schedule, which raises concerns of compromised protection. 2 As a consequence of these factors, it remains important for women, regardless of their vaccination status, to continue to undergo cervical cancer screening.
A study reported that almost all women (96%) who participated in the 2008 US Health Information National Trend Survey were aware of the need to continue cervical cancer screening after HPV vaccination. 3 However, a previous report suggested that vaccination may lower women's perception of their risk for the development of HPV-related diseases, affecting their motivation to be screened for cervical cancer after vaccination. 4 This is concerning because a recent simulation study suggested that missed cervical intraepithelial neoplasia II-III cases could progress to cancer if vaccinated women are less likely to get screened. 5 Although the findings of several surveys suggest that vaccination is generally not associated with a reduced willingness for screening, 3, [6] [7] [8] actual screening behaviors after receipt of the HPV vaccine have not been examined comprehensively. Two studies in the United States have reported a positive association between vaccination and subsequent screening, but these studies were not designed to elucidate the nature of this relationship, which requires accounting for important differences in clinical and utilization histories between women with and without vaccination. 9, 10 To address these gaps in the literature, we examined the relationship between HPV vaccination and subsequent screening initiation and adherence to recommended screening intervals among female members of Kaiser Permanente Southern California (KPSC). We took advantage of KPSC's comprehensive electronic medical records to assess women's vaccination and screening 
Materials and Methods

Study setting and population
KPSC is the largest integrated healthcare delivery system in Southern California, serving >4 million members who are broadly representative of the racial/ ethnic and socioeconomic diversity of the population in this geographic area.
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KPSC provides comprehensive healthcare services to its members; by nature of the prepaid managed care system, members have comparable access to healthcare. Preventive measures that include HPV vaccination and cervical cancer screening are offered without additional out-of-pocket cost. KPSC's cervical cancer screening guidelines generally follow the national guidelines that recommend the initiation of screening at age 21 years. In 2004, KPSC adopted HPV cotesting for women at !30 years old and HPV reflex testing for women who are 21e29 years old. Subsequent screening is recommended every 3 years. This study was approved by the KSPC Institutional Review Board. The Strengthening the Reporting of Observational Studies in Epidemiology statements were followed for the preparation of this article. 12 A retrospective cohort study design was used to examine the association between HPV vaccination and subsequent cervical cancer screening initiation and adherence to recommended screening intervals. Two separate, nonoverlapping cohorts of women were identified to examine these behaviors between calendar years 2010 and 2013. The eligibility requirements for entry into the 2 cohorts were guided by agerelated cervical cancer screening recommendations and the timing of the approval and subsequent availability of the HPV vaccine.
For the evaluation of screening initiation, all female KPSC members who reached age 21 years between 2010 and 2013 were eligible for inclusion. Followup evaluation started for these women at age 21 years (study baseline), which is the age for screening initiation as recommended by current clinical guidelines. 13 To ensure complete capture of vaccination history, women were excluded if they did not have continuous KPSC membership between June 2006 when the HPV vaccine was first approved by the US Food and Drug Administration 14 and the study baseline. Women were also excluded if, before baseline, they had a hysterectomy in which the cervix was removed, they had cervical cancer, or they had initiated cytologybased screening before the guidelinerecommended age of 21 years. Women were observed from study baseline to the initiation of Papanicolaou screening, the end of the observation period (December 31, 2013), or a censoring event (ie, HPV vaccination after baseline, hysterectomy, termination of KPSC membership, or death), whichever came first.
For the evaluation of adherence to recommended screening intervals, all female KPSC members who reached any age between 25 and 30 years in 2010 were eligible for inclusion. This age range was chosen to ensure that all subjects were screening eligible (ie, !21 years old) and vaccine eligible (ie, 26 years old) at the time when the vaccine was introduced. Follow-up evaluation started for these women in year 2010 (study baseline). The same exclusion criteria described earlier were also applied to this cohort, except that women with Papanicolaou screening before baseline were not excluded. Women were followed from study baseline to December 31, 2013, or censoring events (ie, HPV vaccination after baseline, an abnormal Papanicolaou test result [which would place the woman on a surveillance schedule instead of a screening schedule], hysterectomy, termination of KPSC membership, or death), whichever came first.
Data collection
The exposure of interest was HPV vaccination and included the number of doses received. The outcomes of interest were the initiation of Papanicolaou screening and adherence to screening interval. In addition, information on the following potential confounders was collected: race/ethnicity; census blocklevel education and income level; Medicaid enrollment; primary care provider's specialty and sex; healthcare use in the year before baseline, which included the number of office visits, any emergency room visit or hospitalization, and influenza vaccination; gynecologic history that included history of oral contraceptive use, pregnancy, and sexually transmitted infections (STIs), specifically chlamydia, gonorrhea, syphilis and herpes; and primary medical center. All data were obtained from KPSC's electronic medical records that include clinical databases on immunization, laboratory tests, diagnoses, procedures, pharmacy, utilization (health care use), and providers.
Statistical analysis
The distributions of demographic and clinical characteristics of the study cohorts were calculated by HPV vaccination status; differences were assessed with the t-test or chi-square test. The incidence rate of screening initiation was calculated by HPV vaccination status. The associations between HPV vaccination status (yes vs no and by dose) and screening initiation were examined with the use of bivariate and multivariable Cox models that were adjusted for all potential confounders described earlier (categories/forms of each confounder that were adjusted for are shown in Table 1 ). Stratified analyses by race/ethnicity were also conducted.
Although current cervical cancer screening guidelines recommend screening initiation at age 21 years, 13 earlier guidelines also recommended screening for those sexually active for 3 years before age 21 years. 15 Thus, in a sensitivity analysis, screening initiation at age 18 years was examined in a separate cohort of women who reached 18 years between 2010 and 2013. The same exclusion criteria were applied to this cohort as in the primary analysis. Furthermore, because the requirement of continuous membership from 2006 led to exclusion of a large proportion of initially eligible women; an additional sensitivity analysis that included all women, regardless of their length of membership, was also conducted.
Original Research GYNECOLOGY ajog.org A person-timeebased approach for measuring adherence to preventive services, called the Prevention Index (PI) was used to evaluate adherence to cervical cancer screening intervals. Details of the PI method have been described elsewhere. 16, 17 Briefly, the PI represents the proportion (range, 0e100%) of "screening up-to-date" person-time in the study period. For example, Papanicolaou screening is recommended every 3 years. 13 Thus, for a study subject, the 36 months after a Papanicolaou test is considered "up-to-date" person-time, and the time between month 37 and receipt of the next Papanicolaou test is considered "not up-to-date" persontime. For this study, the PI for Papanicolaou screening was calculated for each woman in the interval adherence cohort between 2010 and 2013, which took into account the date of their Papanicolaou screening before study baseline. The distribution of the PI was then calculated by HPV vaccination status. Because the distribution of the PI was skewed highly toward 100%, a dichotomized outcome of 85% was used as the cutoff in the analysis, which was the mean among unvaccinated women. The association between HPV vaccination (yes/no and by dose) and screening adherence was evaluated with the use of bivariate and multivariable logistic regression and adjusted for potential confounders (Table 2) . Stratified analyses by race/ ethnicity were also conducted. In a sensitivity analysis, the analyses were repeated and were restricted to women who did not have an abnormal Papanicolaou screening result before study baseline to exclude those women who might have received a Papanicolaou test for surveillance rather than for screening. Furthermore, an additional sensitivity analysis that included all women, regardless of their length of membership, was also conducted. All analyses were conducted with the use of SAS software (version 9.3; SAS Institute Inc, Cary, NC).
Results
A total of 27,352 women were included in the analysis that examined HPV vaccination and the initiation of Papanicolaou screening. Figure 1 details the study population inclusion and exclusion. A total of 28,262 person-years of follow-up evaluations were observed. Demographic and clinical characteristics of the study population are shown in Table 1 . HPV-vaccinated women were more likely to be of Hispanic ethnicity, have higher healthcare use, and have a history of oral contraceptive use, pregnancy, or STIs compared with those without HPV vaccination. Almost twothirds of the HPV-vaccinated women received !3 doses.
During the study period, 38% and 31% of women with and without any HPV vaccination initiated screening, respectively. The incidence of screening initiation was 439 and 239 per 1000 person-years among those with and without any HPV vaccination, respectively. Figure 2 shows the cumulative incidence of screening initiation after women reached 21 years old by HPV vaccination dose. HPV vaccination was associated positively with screening initiation in both the bivariate and multivariable Cox models (Table 3) ; the adjusted hazard ratios (HR) for any vaccination was 1.46 (95% confidence interval [CI], 1.40e1.53). There was a positive dose-response relationship between the number of HPV vaccine doses and screening initiation; HRs for 1, 2, and !3 doses compared with none were 1.19 (95% CI, 1.11e1.28), 1.44 (95% CI, 1.34e1.53), and 1.57 (95% CI, 1.50e1.65), respectively. Similar associations between HPV vaccination and Papanicolaou screening initiation were found in the analyses that were stratified by racial/ethnic groups and in the sensitivity analyses that evaluated screening initiation beginning at age 18 years and when women were included regardless of length of membership. 
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A total of 41,328 women were included in the analysis that evaluated HPV vaccination and adherence to recommended screening intervals. Figure 1 details the study population inclusion and exclusion. A total of 129,246 personyears of follow-up evaluations were observed. Table 2 shows the demographic and clinical characteristics of this cohort. HPV-vaccinated women were more likely to have higher healthcare use in general (except hospitalization) and a history of oral contraceptive use and STIs.
The PI measure for Papanicolaou screening was high, with a median of 100% (range, 0e100%) in both vaccinated and unvaccinated women. The 25th percentiles for the PI were 94% and 84% in those with and without HPV vaccination, respectively. In the logistic regression that evaluated the risk of PI !85% vs PI <85% (reference group), receipt of any HPV vaccination was associated positively with a higher PI in both the crude and adjusted analyses (adjusted odds ratio, 1.60 [95% CI, 1.49e1.72]; Table 4 ). Women who received 2 or !3 doses, but not those who received only 1 dose, were more likely to have had a higher PI score compared with those with no HPV vaccination: adjusted odds ratios for 1, 2, and !3 doses were 0.93 (95% CI, 0.83e1.04), 1.73 (95% CI, 1.52e1.97) and 2.29 (95% CI, 2.05e2.56), respectively. Similar results were obtained in the analyses that were stratified by racial/ethnic groups and in the sensitivity analyses that excluded women who had an abnormal Papanicolaou test results before baseline or that included all women regardless of their length of membership (data not shown).
Comment
We found that HPV-vaccinated women in this integrated healthcare setting were more likely than unvaccinated women to initiate cervical cancer screening, independent of demographics, gynecologic history, provider type, and pattern of healthcare use. Vaccinated women were also more likely to adhere to the recommended cervical cancer screening interval. Our findings underscore a potential emerging disparity in protection from cervical cancer in the HPV vaccination era: unvaccinated women have a greater need for proper screening to help prevent cervical cancer; however, if they are both unvaccinated and less likely to adhere to 
Screening initiation probability
Cumulative incidence curve and 95% confidence interval band of screening initiation probability by dose history in the screening initiation evaluation cohort. The black line represents 3þ doses; the green line represents 2 doses; the red line represents 1 dose; the blue line represents 0 doses (unvaccinated). Original Research GYNECOLOGY ajog.org screening, they risk being disproportionally affected by the disease. Thus, the results of this study suggest the need to prioritize interventions to improve vaccination rates and/or cervical cancer screening among this at-risk, unvaccinated population.
Several potential explanations exist for our findings. Women with a more positive attitude toward preventive services may be more likely to obtain both vaccination and screening. 18 It is also possible that women with primary care providers who emphasize preventive recommendations are more likely to use preventive services. In addition, if providers emphasized the need for screening while administering the vaccine, then the vaccination event would have served as an educational opportunity and prompted the increased uptake of screening. Qualitative studies to understand patient and provider perspectives about vaccination and screening may help further clarify areas for targeted intervention to prevent cervical cancer in subgroups that underuse preventive services.
Of studies that examined screening behaviors after vaccination, Beer et al 19 found that vaccinated women were more likely to participate in cervical cancer screening than were unvaccinated women in the United Kingdom. On the other hand, Budd et al 20 reported lower screening rates in vaccinated women than in unvaccinated women in Australia. However, both the United Kingdom and Australia have nationwide HPV vaccination programs. Consequently, their findings may not generalize to women in the United States. Paynter et al 10 reported a higher level of screening in vaccinated women than in unvaccinated women in a safety net healthcare system in Kansas City. Using US administrative claim data, Hirth et al 9 reported a positive dose response by number of HPV vaccines received with subsequent Papanicolaou screening. These observations generally are consistent with ours, despite the differences in healthcare settings (ie, safety net, diverse private insurance plans, and an integrated healthcare system with relatively equal access), which suggest that the phenomenon may be widespread across diverse US populations. However, none of the previous studies accounted for important differences between vaccinated and unvaccinated women in their gynecologic histories, STIs, healthcare use, and use of other preventive services. Our study adds to the literature by demonstrating that the association cannot be explained by confounding because of differences in encounters with the healthcare system or a history of gynecologic health. Instead, our results lend support to the influence of attitude/personal belief factors and a potential causal role of HPV vaccination in the uptake of screening services, as discussed. These findings should further inform investigation into effective interventions to address under-vaccination and under-screening among women who are at risk for cervical cancer.
There are several potential limitations to be considered when interpreting the results of this study. First, although we controlled for some a Odds ratio for the Prevention Index outcome !0.85 vs <0.85 (reference group); b Model adjusted for race/ethnicity (white, black, Hispanic, Asian, other/unknown), census block income level (median household income: $45,000, $45,001 e$80,000, >$80,000), and education (% adults with high school degree or above: 0e50%, 51e75%, 76e100%); Medicaid enrollment (yes/no); primary care provider's specialty (pediatrician, family medicine, internal medicine, and others) and sex; healthcare use in the 12 months before baseline (number of office visits, any emergency room visit, any hospitalization); influenza vaccination in the 12 months before baseline; women's gynecologic history before baseline (oral contraceptive use, pregnancy, and sexually transmitted infections, specifically chlamydia, gonorrhea, syphilis, and herpes), and women's primary medical center. Chao et al. HPV vaccine and Papanicolaou screening. Am J Obstet Gynecol 2017.
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indicators of sexual activity, we do not know whether the women were sexually active or not. Those women not sexually active may be less likely to obtain both vaccination and screening. However, the prevalence of HPV vaccination in our cohort was lower than the prevalence of sexually active young women that have been reported on national surveys, 21 which suggests that this is unlikely to explain our results entirely. Second, we were unable to evaluate screening uptake among women who were vaccinated at 11e12 years old (the recommended age range for HPV vaccination) because these women had not yet become screening eligible in the study follow-up period. Because the vaccination decision for girls 11e12 years old is primarily made by parents, it is unclear whether the positive association between vaccination and screening behavior that we observed here is generalizable to women who first received the vaccine at an earlier age. In fact, Paynter et al 10 reported that women who were vaccinated closer to age 21 years were more likely to get screening than those vaccinated at age 14 years. Thus, future studies are needed to confirm the association between vaccination in the recommended age range and subsequent screening behavior. Third, although we required continuous KPSC membership between 2006 and study baseline, it is possible that women obtained vaccination and/or cervical cancer screening outside of the health plan (eg, in school/university medical facilities, Planned Parenthood). This could lead to misclassification and potential bias away from the null if those who received HPV vaccine outside of KPSC were also more likely to receive outside cervical cancer screening services. However, a recent member survey found that HPV vaccine and Papanicolaou screening use outside of KPSC is infrequent (unpublished data). Fourth, the requirement of continuous membership may lead to possible selection bias. Nevertheless, sensitivity analyses that included all women regardless of their length of membership provided the same results, thus, offering some assurance about our conclusions. Last, our 4-year study period (2010e2013) is relatively short for evaluating adherence, given cervical cancer screening intervals are 3 years long. However, this limitation is unlikely to affect the validity of our comparisons by vaccination status.
Our study has several important strengths that include the use of comprehensive electronic medical records to capture demographic and clinical characteristics that are important confounders, analyses that were conducted in a population with comparable access to care that eliminated the confounding because of differential healthcare access, and the fact that the study provided real world data in a community-based healthcare setting.
In conclusion, women who were HPV vaccinated in an integrated healthcare setting were more likely than unvaccinated women to be screened subsequently for cervical cancer. Our data identify a potential emerging disparity in cervical cancer prevention efforts. The public health implications of these screening patterns must be investigated further. Qualitative studies could identify motivations and barriers that are relevant to cervical cancer screening and inform potential targets for future interventions. Finally, as called for in the recent statement from the American Society of Clinical Oncology, a significantly enhanced HPV vaccination rate in the US population may be the ultimate goal to reduce cervical cancer disparities and the human and economic burden of cervical cancer.
